Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02956798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SAbR For Oligometastatic Renal Cell Carcinoma

StatusCompleted
PhaseNot applicable
Started2018-07-19
View on ClinicalTrials.gov ↗
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy. Primary Objectives: • To evaluate the delay in time to start of systemic therapy (TTST) as a surrogate of progression free survival (PFS), defined as the time from the first day of SAbR to start of systemic therapy. Secondary Objective: * To evaluate the modified progression-free survival (mPFS) for patients with oligometastatic renal cell carcinoma who are treated with SAbR. * To evaluate the overall survival (OS) * To evaluate the cancer specific survival (CSS) * To evaluate the local control rate of irradiated lesions. * To measure the health-related quality of life (HRQOL).

Amendment history 5 changes detected by DataLookout

2026-09-01
Trial completed
2026-09-01
Phase changed: Phase 2 → not applicable
2026-09-01
Primary endpoint(s) modified
WasTime to start of systemic therapy (TTST)
NowPercentage of Participants With Delay in Time to Start of Systemic Therapy (TTST)
2026-09-01
Primary completion confirmed: January 2024 (last estimated December 2025)
2026-09-01
Results posted: 2026-08-31
Trial Details
NCT Number NCT02956798
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Oligometastatic Renal Cell Carcinoma
Enrollment 23 participants
Start Date 2018-07-19
Primary Completion 2024-01-24 (estimated)
Study Completion 2024-01-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-31